Pharma 2023 Marketing the Future

Abstract

As stated in "Pharma 2023, The Vision," the pharmaceutical industry is changing drastically. Seven key trends are changing the pharmaceutical sector. This includes a growing emphasis on specialty drugs, a growing need for personalized medicine, a growing reliance on digital technologies, a growing emphasis on patient eccentricities, a growing attention on cost containment, and a growing emphasis on data-driven decision-making. One recent study estimates that, between 2005 and 2010, total actual spending on pharmaceutical advertising rose from US$15.4 billion to US$35.9 billion in the US (the only country for which expenditure on all major advertising and sales activities is available). Another study suggests that the actual figure (including conferences and e-promotion) is closer to US$65.6 billion in the same period. However, many of the industry's largest markets are now saturated with sales representatives, and its promotional strategies are becoming increasingly more effective.

References

1. Price water residence coopers, "Pharma2020, the vision- which Path will you take"June 2007
2. Julie M Donohue,Marisa cevasco et.al " A Decade of Direct-to-Consumer marketing of Prescription Drugs" The New England Journal of Medicine, Volume 357, No7 August 16, 2007, 673- 681
3. Mare- Andre Gagnon & Joel Lexchin, " The fee of Pushing Pills, A New Estimate of Pharmaceutical advertising Expenditure in the united state" Plos Med,volume5,issue1 January 2008 29-33.
4. "The State of the Sales Industry: Trends, Challenges, and Opportunities." Salesforce, www.salesforce.com/blog/2018/04/state-of-sales-industry-trends-challenges-opportunities.html.
5. Verispan" 2006 yr in Review" (April 11, 2007) American Medical Association," Physician Characteristics and Distribution in the US,2006.
6. IMS " intelligence,360, Global Pharmaceutical perspective,2005 February 2006
7. "Marketing intelligence in Pharmaceutical Industry is badly needed" accessed August 18, 2008
8. Consumer International, op. cit.Health. eight world fitness organization, sixtieth world fitness Assembly Assembly," procedure in the rational use of medication " May 23 2007 accessed August 31.
9. World Health Organization. (2020). Resolution WHA73.1: Inaccurate, deceptive or unethical merchandising of medicinal drug products.
10. World Health Organization. (2020). Noncommunicable diseases. Retrieved from https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
11. Organization for financial cooperation and improvement OECD fitness information 2008 June 2008
12. Lynne Taylor," Senate consignment the first step to " USNICE" Pharma Times August 10, 2008
13. Sanchia Berg," Herceptin, Was affected person strength key" BBC News June 9, 2006, accessed November 11, 2008
14. National complete most cancers Network," Oncology results Database Project " accessed November 28, 2008, Professional / results database .asp, Bernie Monegain " AMGA seck Power in mixed data" Healthcare IT News February 01, 2006, accessed November 28, 2008, SAE consortium press release," International Serious Adverse Events Consortium ( SAEC) launches Global Research collaboration to become aware of Genetic Makers Related to Adverse Drug Reaction" September 27, 2007, accessed November 28, 2008, SAEC- Announcement - Press Release 2007 09- 27 PDF
15. Andrew Pollack," Pricing Pills via the Result" The New York Times ( July 14, 2007) accessed May 19, 2008,(2007/07/14 commercial enterprise / 14 drug rate HTML.Slogan.
16. "NICE Endorses Pioneering Lucentis Reimbursement Scheme Reject Macugen in moist AMD? Global perception April 3, 2008, accessed October 22, 2008.
17. BBC News " Deal reached on NHS drug prices" November 19, 2008, accessed November 28, 2008
18. "UK Government Announces New Flexible Pricing System for New Medicines." Pharmaceutical Technology, 24 June 2020.
19. "AIDS in Africa: The Cost of Treatment." World Health Organization, www.who.int/hiv/pub/prev_care/aids_africa_cost.html.
20. Kumar, A. (2020). The Impact of Social Media on Businesses. International Journal of Business and Management, 15(2), 1-10. doi:10.5539/ijbm.v15n2p1
21. Reference: Garnier, J. P. (2008). R&D at GlaxoSmithKline: A New Model for Pharmaceutical Discovery and Development. Harvard Business Review, 86(7/8), 78-86.
22. Reference: Munos, B. (2009). Success in the pharmaceutical industry depends upon the random occurrence of a few “black swan” products. Nature Reviews Drug Discovery, 8(7), 545-546. doi:10.1038/nrd2790